Rekah 2025: Derech Chaim Buys Time, but the Core Business Still Hasn't Stabilized

Company Overview

Rekah is not just a generic-drug manufacturer. It is a three-engine group with very different economic profiles: core products, which carry the pharmaceutical and dermo-cosmetic thesis; distribution, which is a logistics and commercial arm for third-party products; and a special segment, which is mainly the Mifal HaPayis lottery-distribution franchise in the Jerusalem area. In 2025, core products contributed 69.2% of revenue, distribution 25.2%, and the special segment 5.7%. That matters because not every shekel of revenue has the same quality, and not every source of profit belongs to the same thesis.

Some things are clearly working. The group has a broad commercial footprint, institutional and private customer relationships, a daily distribution system that reaches roughly 1,500 customers, brand and import activity built through the TOL and Moraz acquisitions, and a strategically important Clalit contract under the Derech Chaim brand that was renewed in January 2026 for 6 years with a 4-year extension option. This is not a company without operating engines.

But the active bottleneck sits elsewhere: the core business still cannot translate that platform into profit and cash. In 2025, core-products revenue fell 8.4% to NIS 208.2 million, and the operating loss in that segment widened to NIS 12.1 million. At the same time, cash fell to just NIS 4.3 million, inventory rose to NIS 91.0 million, and finished-goods inventory jumped 32.8% to NIS 52.0 million. That is no longer just a procurement or raw-material story. It is a question of production throughput, sell-through, and how quickly inventory turns back into cash.

That is the key screen-level takeaway. The renewed Derech Chaim agreement is positive. The improved profit in the special segment is also easy to like at first glance. But neither proves that the core business has returned to economic stability. Rekah enters 2026 with better commercial continuity, but still without proof that the core is back to generating net profit and cash.

What matters immediately:

• The Derech Chaim renewal improves continuity, but it was signed with no material change in the existing terms. It is a stability anchor, not a new pricing engine.
• The top two customers rose to 39.7% of sales from 35.5% in 2024. Channel power has not weakened.
• Inventory increased mainly through finished goods, not raw materials. That shifts the pressure from procurement into sell-through.
• Debt is not near a covenant wall, but cash flexibility is still tight: low cash, NIS 89.4 million of net financial debt, and NIS 9.6 million of annual lease-related cash outflow.

Quick Economic Map

Actionability Constraint

There is a practical market filter here before getting into the report itself: the stock is illiquid. On the latest trading day in the prepared market snapshot, daily turnover was about NIS 50.6 thousand, and short-interest data was essentially negligible across the period. That means sharp price moves may say as much about shallow trading depth as about a real change in the business read.

Events And Triggers

The first trigger: the Derech Chaim renewal is the clearest post-balance-sheet event around this report. In January 2026, Vitamed and Clalit signed a new agreement to continue manufacturing, selling, and distributing products under the Derech Chaim brand for 6 years, with a 4-year extension option for Clalit. The company stresses that there was no material change in the existing terms. That matters because it removes the risk of losing an important activity line and supports continuity inside the core-products segment. But precisely because the terms did not materially change, it should not be read as evidence of stronger pricing power or better unit economics. It is continuity, not repricing.

The second trigger: contracted backlog for 2026 starts from a lower base. Based on binding agreements with Clalit, Leumit, Teva, and Sarel, contracted backlog stood at NIS 47.2 million at the end of 2025, down from NIS 53.5 million at the end of 2024. By the report date it had already declined to NIS 29.4 million. Part of that reflects timing inside 2026, but the economic message is still clear: forward visibility did not widen. It narrowed. That is why the Derech Chaim renewal matters mostly because it prevents further deterioration in continuity, not because it removes the need to prove actual sales in the coming quarters.

The third trigger: the special segment showed better profit, but not because sales accelerated. Revenue in that segment was nearly flat at NIS 17.0 million, while operating profit rose to NIS 4.4 million from NIS 3.1 million mainly because amortization of the Mifal HaPayis franchise fee ended. The improvement is real, but it belongs more to the accounting layer of the group than to the core pharma thesis. A superficial read can see better segment profit and assume stabilization. That would be the wrong conclusion. This does not fix the core problem.

The fourth trigger: in July 2025, Rekah signed an amendment relating to TOL under which it agreed to pay about NIS 5.5 million in equal instalments in September 2025, June 2026, and June 2027 as a final payment for the remaining additional contingent consideration. This is not just a footnote. It is a reminder that the acquisition wave still carries a real cash tail.

What the market may miss on first read is that the genuinely positive event, the Derech Chaim renewal, does not arrive on its own. It arrives together with a smaller binding backlog, heavier inventory, and a core business that is still in operating loss. Anyone looking for one headline that suddenly reopens the equity story is probably looking in the wrong place. This setup needs a sequence of proofs, not one contract announcement.

Efficiency, Profitability, And Competition

The right read of 2025 is not simply that sales fell and the company lost money. That is too flat. The real story is that the quality gap between the segments widened. The main segment, the one that is supposed to justify the thesis around manufacturing, brands, imports, and commercial capability, weakened. The secondary segments held up better, but not nearly enough to cover for it.

At the consolidated level, revenue fell 6.4% to NIS 301.0 million. Gross profit fell 3.3% to NIS 69.6 million, but gross margin actually edged up to 23.1% from 22.4%. On the surface, that looks manageable. In practice, it is one of the places where the full-year view is misleading. In Q4, revenue was almost flat and rose to NIS 76.9 million, but gross profit fell 16% to NIS 16.3 million, and gross margin dropped to 21.2% from 25.5%. So the year-end run rate already looked weaker than the softened annual number.

What Actually Hurt The Core

Management explains the decline in core products through shortages in some raw materials, difficulty receiving goods from abroad, and weaker exports in some products because of seasonality in certain target markets. That is not a technical side note. In Q4, the company explicitly linked the deterioration in gross profit to lower production output because of limited material availability. So 2025 should be read as a year in which the issue was not only demand, but also utilization and execution.

The key number is that core-products revenue fell to NIS 208.2 million, while segment operating loss widened from NIS 8.6 million to NIS 12.1 million. By contrast, the distribution segment fell only modestly in revenue and returned to an operating profit of NIS 1.5 million after a loss in 2024, helped in part by the fact that the prior year carried a roughly NIS 2.0 million commercial-dispute provision and about NIS 0.6 million of other one-offs. The special segment, as noted, improved because amortization ended. So if the group is taken apart properly, the picture is not one of broad collapse. It is a weaker core, partially cushioned by secondary layers.

Channel Power Has Not Eased

Another point the market may miss sits in the customer base. In 2025, the group’s top two customers generated NIS 119.5 million of sales, or 39.7% of total revenue, versus NIS 114.2 million and 35.5% in 2024. One customer declined to NIS 52.1 million, but the other rose to NIS 67.5 million and reached 22.4% of total sales on its own. The company does not disclose the identities, so it would be wrong to guess. But the economic conclusion is clear even without names: dependence on two major revenue channels has grown.

That connects directly to competition and pricing power. The company itself says that its ability to pass through higher input costs is limited by market structure, price-regulation mechanisms, and broader regulatory constraints. Put simply, if imports become more expensive or supply chains tighten, Rekah cannot necessarily just raise prices. The pressure stays inside the margin.

Who Pays For Promotions

There is one disclosure in distribution that slightly softens the quality-of-growth concern. The company describes seasonal promotions with discounted prices and easier credit terms, but says these are executed Back to Back with suppliers and therefore do not materially change gross margin on those promotional sales. That matters because it suggests that, at least in the distribution layer, Rekah is not openly buying volume through a unilateral sacrifice of margin. The main pressure in 2025 therefore appears to have been less about overly aggressive distribution pricing and more about weakness in the core business itself.

Cash Flow, Debt, And Capital Structure

This is the heart of the story. Covenants are not shouting, but the cash balance is. Anyone who reads only the covenant section will come away too comfortable. The company does indeed comply with all financial covenants, with tangible equity of NIS 80.8 million and a current ratio of 1.53 against a minimum of 1.0. That is far from an immediate banking event. But Rekah’s financing thesis is not being tested right now through the question of whether a lender stops it. It is being tested through how much real room is left after actual cash uses.

Cash Framing: all-in cash flexibility

This is the right place to use the all-in cash flexibility lens. Cash flow from operations was NIS 12.9 million in 2025. That sounds manageable until the full list of uses is included. Investing cash flow consumed NIS 6.3 million, financing cash flow consumed NIS 9.4 million, and the year-end cash balance fell by NIS 2.7 million to only NIS 4.3 million. This is not the picture of a business building a comfortable cash buffer.

A more generous view could focus on the NIS 12.9 million of operating cash flow and say the business still produces cash. But that would still be only half the picture. In 2025 the company paid total lease-related cash outflow of NIS 9.6 million, of which NIS 7.5 million was lease principal. It also paid NIS 2.2 million of contingent consideration. So even the operating cash flow line cannot be treated as if it stayed available inside the business.

Where The Cash Conversion Got Stuck

The working-capital note gives the sharpest clue. Inventory rose 10.3% to NIS 91.0 million, but the composition changed materially: raw materials and packaging fell 25.8% to NIS 26.6 million, while finished goods jumped 32.8% to NIS 52.0 million. That matters. If the inventory build sat mainly in raw materials, the story could be framed more as procurement strategy, import timing, or longer lead times. Here, most of the weight moved into finished goods.

That changes the nature of the concern. The issue now looks less like raw-material procurement alone and more like a gap between production, sell-through, and revenue recognition. The cash flow statement tells the same story: the largest operating working-capital drag was the NIS 8.5 million increase in inventory, while receivables barely moved. The current cash squeeze is therefore much more about inventory turn than about collections.

Debt Is Not Crushing, But It Is More Rate Sensitive

Another non-obvious finding is the change in the debt mix. Total short-term and long-term bank and other credit rose to NIS 84.4 million from NIS 78.8 million. The fixed-rate portion fell to NIS 43.2 million from NIS 54.1 million, while the floating-rate prime-linked portion jumped to NIS 41.2 million from NIS 24.7 million. In other words, even though net financing expense fell to NIS 4.0 million, partly because of loan repayments and contingent-consideration revaluation, the balance sheet became more sensitive to interest rates.

Two more layers matter here. First, net financial debt rose to NIS 89.4 million from NIS 86.1 million, mainly because cash declined. Second, contingent consideration still stood at NIS 15.3 million at year-end. So even if the covenant picture looks relatively comfortable, the balance sheet still carries real forward cash claims.

The bottom line in this section is straightforward: Rekah’s immediate risk is not covenant breach. It is erosion of financial flexibility. To get back to a more comfortable position, the company does not only need to remain within bank limits. It also needs a combination of better core performance, lower inventory, and a stable cash balance.

Outlook And Forward View

Four Points That Will Decide 2026

• The Derech Chaim renewal improves continuity, but because the terms did not materially change it cannot by itself deliver a margin step-up.
• Management talks about more than five new imported products in 2026, but also says it cannot estimate the registration odds or actual sales potential.
• The Moraz and TOL synergy story matters, but two to four years after those acquisitions, the market now needs to see it in gross profit, inventory, and cash, not in strategic language.
• Institutional visibility into 2026 is lower, so the next reports will be judged much more on actual sell-through than on product-pipeline statements.

2026 looks like a bridge year, but one that quickly has to start looking like a proof year. Management presents a clear list of levers: expanded registration and development, especially in steroids and eye products; launch of more than five imported products subject to regulatory approvals; export expansion; and deeper operational integration of Moraz and TOL. Strategically, the direction is coherent. The problem is that the proof gap has widened.

The reason the proof gap has widened is that management itself leaves the key caveat in place: it cannot currently estimate either the probability of approval or the actual sales potential of those import and registration lines. So the market gets a set of initiatives, but not a reliable quantitative frame on which to build 2026. In that situation, anyone capitalizing the pipeline too aggressively is probably moving too early.

Q4 Is The Right Base For Reading The Next Year

Q4 matters more than usual here. Revenue was up only 1%, but gross profit was down 16%, EBITDA was down 35%, and net loss deepened to NIS 6.3 million. That is the real starting point for 2026. Not the almost-flat consolidated top line, but a year-end quarter where weaker throughput and limited material availability fed directly into lower margin quality.

The right way to read the next few reports is therefore through four simple checkpoints:

What Could Improve The Read

There is also a strong counter-thesis, and it should be taken seriously. If raw-material availability improves, if more than five planned launches actually get approved and start selling, and if Moraz and TOL synergies begin to show up in inventory turn and commercial execution, Rekah does have a platform that could generate a sharper swing than the current numbers imply. Distribution is back to profit. The special segment is stable. Derech Chaim is a commercial anchor. The company still has brands, facilities, and wide customer access.

But for that scenario to gain credibility, the market will need hard evidence. Not another line about growth engines, but actual improvement in the core, in inventory, and in cash. Until then, optimism remains a thesis, not proof.

Risks

The first risk is channel concentration. The top two customers already account for almost 40% of revenue, and the company itself says its ability to pass on higher input costs is constrained by market structure and regulation. That is not a comfortable combination: bigger customers, weaker pricing freedom.

The second risk is supply chain and currency exposure. Some raw materials are imported, a weaker shekel against the dollar and the euro can increase input costs, and the company describes higher logistics costs and limited material availability. The group does have a partial natural hedge through export revenues in those currencies, but this is not a full shield. When the core segment is already in operating loss, even moderate supply-chain pressure matters more.

The third risk is financing stress without a covenant event. That distinction matters. As of year-end 2025 the company still complies with all financial covenants, so the near-term risk is not an immediate bank trigger. But NIS 4.3 million of cash, NIS 9.6 million of lease-related cash outflow, NIS 15.3 million of contingent consideration, and a more prime-linked debt mix already create a tighter margin for error.

The fourth risk is regulatory and commercial execution risk. Management anchors part of the forward story in product launches and imports, but also says outright that it cannot estimate the registration odds or sales potential at this stage. The pipeline exists, but it should not be given full credit before it reaches the shelf and the cash flow line.

The fifth risk is low trading liquidity. When turnover is thin and short interest is negligible, the market produces fewer strong external signals, and price reaction itself becomes less informative. That does not change the business, but it does change the way the story trades in the near term.

Conclusions

Rekah enters 2026 with a renewed Derech Chaim contract, a broader platform than a quick glance suggests, and relatively comfortable covenant compliance. At the same time, the core business is still losing money, inventory is sitting too close to the shelf, and cash is too low to support many more quarters of waiting. In the short term the market may respond positively to the renewed contract and the recovery in distribution, but the deeper read will still depend on whether the core, inventory, and cash all start moving in the right direction together.

Current thesis: Derech Chaim buys Rekah time and commercial continuity, but until the core business returns to profit and cash, this remains a broad platform with an active operating and cash bottleneck.

What changed versus the more comfortable 2024 read: the illusion created by a one-off real-estate gain disappeared, and the weakness in the core became clearer through inventory, Q4, and the lower cash balance.

Counter-thesis: if material availability improves, the new import launches convert into sales, and Moraz and TOL synergies finally show up in profit and cash, the market may currently be reading Rekah through one unusually weak year rather than through its forward earning power.

What could change the market read in the short to medium term: not another single contract headline, but a double proof. First, a stop to the decline in core products and a better gross-profit line. Second, lower inventory and a stable cash balance.

Why this matters: the real question at Rekah is not whether it has products, brands, and distribution. It does. The question is whether that structure can now generate operating profit and cash at the listed-group level, rather than just support a wide activity base on paper.

What has to happen over the next 2 to 4 quarters: core sales must stop falling, gross margin has to recover from the weak Q4 level, finished-goods inventory has to convert into actual sales, and cash must stabilize even while leases and contingent-consideration payments continue. If that does not happen, the 2025 read shifts from a bridge-year story into one of deeper structural erosion.